AU2022292722B2 - Anti-csp antibodies - Google Patents

Anti-csp antibodies Download PDF

Info

Publication number
AU2022292722B2
AU2022292722B2 AU2022292722A AU2022292722A AU2022292722B2 AU 2022292722 B2 AU2022292722 B2 AU 2022292722B2 AU 2022292722 A AU2022292722 A AU 2022292722A AU 2022292722 A AU2022292722 A AU 2022292722A AU 2022292722 B2 AU2022292722 B2 AU 2022292722B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022292722A
Other languages
English (en)
Other versions
AU2022292722A1 (en
Inventor
Daniel Eric EMERLING
Randal R. Ketchem
Shaun M. Lippow
Wayne Volkmuth
Katherine L. WILLIAMS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atreca Inc
Original Assignee
Atreca Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atreca Inc filed Critical Atreca Inc
Publication of AU2022292722A1 publication Critical patent/AU2022292722A1/en
Application granted granted Critical
Publication of AU2022292722B2 publication Critical patent/AU2022292722B2/en
Priority to AU2025220692A priority Critical patent/AU2025220692A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022292722A 2021-06-17 2022-06-16 Anti-csp antibodies Active AU2022292722B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025220692A AU2025220692A1 (en) 2021-06-17 2025-08-19 Anti-CSP antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211820P 2021-06-17 2021-06-17
US63/211,820 2021-06-17
PCT/US2022/033877 WO2022266383A1 (en) 2021-06-17 2022-06-16 Anti-csp antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025220692A Division AU2025220692A1 (en) 2021-06-17 2025-08-19 Anti-CSP antibodies

Publications (2)

Publication Number Publication Date
AU2022292722A1 AU2022292722A1 (en) 2024-01-04
AU2022292722B2 true AU2022292722B2 (en) 2025-05-22

Family

ID=84526612

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022292722A Active AU2022292722B2 (en) 2021-06-17 2022-06-16 Anti-csp antibodies
AU2025220692A Pending AU2025220692A1 (en) 2021-06-17 2025-08-19 Anti-CSP antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025220692A Pending AU2025220692A1 (en) 2021-06-17 2025-08-19 Anti-CSP antibodies

Country Status (9)

Country Link
US (2) US11655290B2 (enExample)
EP (1) EP4355774A4 (enExample)
JP (1) JP2024524895A (enExample)
KR (1) KR20240047964A (enExample)
CN (1) CN117940450A (enExample)
AU (2) AU2022292722B2 (enExample)
IL (1) IL309422A (enExample)
MX (1) MX2023014984A (enExample)
WO (1) WO2022266383A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024214379A1 (en) * 2023-02-03 2025-08-21 Atreca, Inc. Anti-csp antibody variants
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180362628A1 (en) * 2016-03-21 2018-12-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
WO2020172220A1 (en) * 2019-02-19 2020-08-27 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2927892A (en) 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CN103732738A (zh) * 2011-04-28 2014-04-16 小利兰斯坦福大学托管委员会 与样品相关的多核苷酸的鉴定
TW201708260A (zh) 2015-07-22 2017-03-01 優瑞卡醫療公司 靶向ｐｓａ胜肽／ｍｈｃ複合體之構築體及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180362628A1 (en) * 2016-03-21 2018-12-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
WO2020172220A1 (en) * 2019-02-19 2020-08-27 Atreca, Inc. Anti-csp antibody variants

Also Published As

Publication number Publication date
EP4355774A4 (en) 2025-05-07
JP2024524895A (ja) 2024-07-09
US20230167169A1 (en) 2023-06-01
NZ806561A (en) 2025-06-27
US11655290B2 (en) 2023-05-23
CN117940450A (zh) 2024-04-26
KR20240047964A (ko) 2024-04-12
IL309422A (en) 2024-02-01
US20230002483A1 (en) 2023-01-05
WO2022266383A1 (en) 2022-12-22
MX2023014984A (es) 2024-03-12
AU2025220692A1 (en) 2025-09-11
AU2022292722A1 (en) 2024-01-04
US12545723B2 (en) 2026-02-10
EP4355774A1 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
JP7331298B2 (ja) 抗体結合ｔｓｌｐ及びその使用
US11440954B2 (en) Optimized anti-TL1A antibodies
TWI852077B (zh) 用於移除造血幹細胞的抗體藥物結合物
JP7711079B2 (ja) Ｉｌ４ｒに結合する抗体とその使用
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
TW201702264A (zh) 結合ｃｄ３８之抗體治療劑
US10858434B2 (en) PD1 binding agents
JP2015038109A (ja) 眼科疾患を治療する方法
EP3360896B1 (en) Antibody to hepatitis b surface antigen and use thereof
JP7538131B2 (ja) 抗ｃｄ７９ｂ抗体、その抗原結合フラグメントおよびそれらの医薬用途
US12545723B2 (en) Anti-CSP antibodies
AU2022262101A1 (en) Antibodies binding trop2 and uses thereof
JP7449390B2 (ja) 抗ｅ－セレクチン抗体、組成物および使用の方法
WO2020221451A1 (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof
US20240166738A1 (en) Anti-tmem106b antibodies for treating and preventing coronavirus infections
US20220195023A1 (en) Anti-csp antibody variants
OA21630A (en) Anti-CSP antibodies.
WO2025194069A1 (en) Anti-csp antibody variants
JP2023520624A (ja) Ｃｔｌａ４に結合する抗体及びその使用
KR20260036054A (ko) 항-csp 항체 변이체
WO2025171256A1 (en) Compositions and methods for treating malaria
KR20240022546A (ko) 항il-36r 항체 및 그의 사용
JP2023526294A (ja) Ｉｌ６ｒに結合する抗体及びその使用
HK40079597B (zh) 结合il4r的抗体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)